The chronic airway inflammation associated with asthma is characterized by infiltration of both T lymphocytes that produce T H 2 cytokines and eosinophilic leukocytes (1) . Large numbers of eosinophils and high concentrations of T H 2 cytokines, such as interleukin-4 (IL-4), IL-5, and IL-13, are thus present in both the airway and bronchial alveolar lavage (BAL) fluid of individuals with asthma. The importance of T H 2 cytokines in asthma has been demonstrated in animal models, in which either disruption of the genes encoding these proteins or their antibody-mediated neutralization prevents eosinophilia and attenuates various pathological changes, such as airway hyperreactivity, associated with this condition (2) . Symptoms of asthma are induced by exposure to specific antigens. Affected individuals produce IgE antibodies to these antigens, and antigen-antibodymediated cross-linking of the IgE receptors on the surface of mast cells and the consequent activation of these cells are suggested to be important in initiation and development of bronchial asthma (3) . Activated mast cells produce a variety of chemical mediators, one of which, prostaglandin D 2 (PGD 2 ), is the major cyclooxygenase metabolite of arachidonic acid produced by these cells in response to antigen challenge (4). PGD 2 is released in large amounts during asthmatic attacks in humans, and it has been proposed as a marker of mast cell activation in asthma (5) . However, the role of PGD 2 in allergic asthma remains unclear. PGD 2 elicits its biological actions through interaction with the PGD receptor (DP), a heterotrimeric GTP-binding protein-coupled, rhodopsin-type receptor that is specific for this PG (6) . To clarify the role of PGD 2 in asthma, we generated and characterized mice deficient in DP.
The mouse DP gene was disrupted by insertion of a neomycin resistance gene into the first coding exon (exon 2) (Fig. 1A) , and mice chimeric for the resulting mutant allele were generated and mated with C57BL/6 animals to produce mice heterozygous for this allele (7) . Interbreeding of the heterozygotes produced homozygous mutant (DP Ϫ/Ϫ ) mice (Fig. 1B) in a ratio expected from Mendelian inheritance, indicating that the lack of a functional DP gene does not result in fetal death. Reverse transcription and polymerase chain reaction (RT-PCR) analysis confirmed a higher molecular weight transcript corresponding to the Neo-inserted DP mRNA in the homozygous mutants (Fig.  1C) . Loss of functional DP protein in these animals was confirmed by a bioassay with tracheal smooth muscle (8) . Whereas PGD 2 and the DP agonist BW245C [5(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl)hydantoin] (9) each induced relaxation of tracheal smooth muscle from wild-type mice, no such effect was apparent in muscle derived from DP Ϫ/Ϫ animals (Fig. 1D) . The DP Genomic DNA from newborn littermates of heterozygote intercrosses was digested with Xba I, and the resulting fragments were subjected to analysis with a Nhe I-Xba I fragment of the genomic DNA as a probe. The positions of 3.6-kb (wild-type) and 4.7-kb (mutant) hybridizing fragments are shown for mice of the indicated genotypes. (C) RT-PCR analysis. Polyadenylated RNA from the ileum of wild-type mice (lanes 1 and 2) and DP Ϫ/Ϫ mice (lanes 3 and 4) was subjected to PCR amplification in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of reverse transcriptase (RT). The estimated positions of nucleotides of 1972 and 889 base pairs (bp) are indicated on the right. (D) Relaxation of tracheal smooth muscle by PGD 2 or BW245C. Tracheal rings from wild-type (top traces) and DP Ϫ/Ϫ (bottom traces) mice were suspended in an organ bath and induced to contract with carbachol. Relaxation in response to 3 M PGD 2 or 100 nM BW245C (or saline) applied at the times indicated by the arrows was assessed.
of genetic background, we backcrossed DP Ϫ/Ϫ animals with C57BL/6 mice for five generations. The resulting heterozygous mice were intercrossed, and progenies of the resulting wild-type and DP Ϫ/Ϫ littermates (N 5 ) were subjected to the analysis below (10) .
The role of DP in asthma was investigated with an ovalbumin (OVA)-induced asthma model in which PGD 2 is generated in response to antigen challenge, as it is in humans with this condition (11) . Wild-type and DP Ϫ/Ϫ mice were sensitized with intraperitoneal (ip) injections of OVA on day 0 and day 12 and were then exposed to aerosolized OVA on days 22, 26, and 30 ( Fig. 2A) (12) ; control animals received saline instead of OVA. To determine the efficiency of this sensitization procedure, we analyzed serum concentrations of IgE. The concentrations of both total IgE and OVAspecific IgE in mice were markedly increased in response to ip injection of OVA and were boosted by subsequent inhalation of OVA; no substantial differences were apparent in this regard between wild-type and DP Ϫ/Ϫ mice (Fig. 2B) . Repeated antigen inhalation in immunized wild-type mice resulted in a significant increase in total cell number in BAL fluid compared with that for the corresponding saline-treated control animals [22.2 (Ϯ10.4) ϫ 10 5 versus 2.5 (Ϯ0.2) ϫ 10 5 , P Ͻ 0.05] (13). The infiltrated cells consisted predominantly of eosinophils, although the number of lymphocytes in the BAL fluid was also significantly increased (Fig. 2C) . In contrast, only marginal increases in the numbers of eosinophils and lymphocytes in BAL fluid were apparent in DP Ϫ/Ϫ mice exposed to OVA challenge (Fig. 2C) . Repeated OVA challenge in this animal model results in the development of airway hyperreactivity. We measured such hyperreactivity to acetylcholine 24 hours after the third inhalation of antigen (14) . The OVA challenge significantly increased the sensitivity to acetylcholine in the wild-type mice, whereas little increase was detected in DP Ϫ/Ϫ animals ( Fig. 2D ).
Given the essential role of T H 2 cytokines in evoking asthmatic responses (2), we measured the concentrations of IL-4, IL-5, and IL-13 in BAL fluid from wild-type and DP Ϫ/Ϫ mice (15) . Challenge with OVA induced significant increases in the concentrations of all three of these T H 2 cytokines in BAL fluid from wildtype mice (Fig. 3 , A through C). Antigen challenge also increased the concentrations of these cytokines in DP Ϫ/Ϫ mice, but to a significantly lesser extent than in wild-type mice. In contrast, OVA challenge induced no difference in the concentration of the T H 1 cytokine interferon-␥ (IFN-␥) in BAL fluid between wild-type and homozygous DP-deficient mice (Fig. 3D) .
In humans with asthma, infiltration of numerous lymphocytes is apparent in the lung and is thought to be responsible for the increased abundance of T H 2 cytokines. Lymphocytes and eosinophils accumulate in the bronchial submucosa and around blood vessels and, in some areas, lymphocytes form bronchus-associated lymphoid tissue (BALT). Histological analysis of OVA-challenged wild-type mice revealed extensive cell infiltration ( Fig. 4A ) and occasional BALT formation ( Fig. 4B ) in the lungs of all animals (16) . In contrast, little cell infiltration was detected in the lungs of OVAchallenged DP Ϫ/Ϫ animals ( Fig. 4C ). We next examined mucus secretion by airway epithelial cells, given that hypersecretion of mucus is one of the characteristic features of asthmatic airways both in humans and animal models (17) . Whereas many mucus-containing cells were apparent in wild-type mice challenged with OVA ( Fig. 4D ), few such cells were detected in antigen-challenged DP Ϫ/Ϫ mice (Fig. 4E ). Finally, we examined the expression and localization of DP in the lung. Northern blot analysis (7) detected little expession of DP in the lung of nonimmunized as well as immunized mice before the antigen challenge (Fig.  5A ). However, the OVA challenge to the airway markedly enhanced the DP expression in the lung. No induction was found in the spleen before and after the antigen challenge. We next performed immunofluorescence and immunoelectron microscopy using a specific antibody to mouse DP (18). Weak DP receptor immunoreactivity was detected in the cells surrounding bronchioles and alveoli of the lung of the immunized wild-type mouse before challenge, and the immunoreactivity was markedly enhanced by the airway exposure to OVA (Fig.  5B ). In contrast, no DP receptor immunoreactivity was detected in the lung of DP Ϫ/Ϫ mice Expression of the DP receptor mRNA was examined in the ileum (lanes 1 to 3), the spleen (lanes 4 to 6), and the lung (lanes 7 to 9) of unimmunized (lanes 1, 4, and 7) and immunized wild-type mice before (lanes 2, 5, and 8) and after (lanes 3, 6, and 9) the OVA challenge. Positions of DP mRNA are indicated. (B) Immunofluorescence microscopy for DP in the lung of immunized wild-type mice before (left) and after (middle) the OVA challenge and in immunized DP Ϫ/Ϫ mice after the challenge (right). Original magnification, ϫ20. (C) Immunoelectron microscopy for DP in the lung of immunized wild-type mice after the OVA challenge. Immunogold particles are seen on the plasma and intracellular membranes of bronchiolar (left) and alveolar (right) epithelial cells. Original magnification, ϫ8000. before and after the challenge. These results not only verified that our gene-targeting strategy successfully disrupted the DP gene, but also confirmed the induction of the DP receptor in the asthmatic lung suggested by the Northern blot analysis. Immunoelectron microscopy further identified the DP receptor-expressing cells as ciliated and nonciliated epithelial cells in the bronchioles and type II alveolar epithelial cells (Fig. 5C ). Moderate DP receptor immunoreactivity was also detected in the type I alveolar epthelial cells and infammatory white blood cells (19) .
We have shown that DP Ϫ/Ϫ mice do not develop asthmatic responses in an OVA-induced asthma model, indicating that PGD 2 and its receptor (DP) are important for such responses. Our observation that the serum concentrations of IgE were similar in immunized wildtype and DP Ϫ/Ϫ mice suggests that the loss of DP does not affect the primary immune response. Indeed, OVA induced the production of similar amounts of T H 2 cytokines by splenocytes prepared from immunized wild-type and DP Ϫ/Ϫ mice (19) . In contrast, the concentrations of such cytokines in BAL fluid after OVA challenge were significantly lower in DP Ϫ/Ϫ mice than in wild-type mice, suggesting that the effect of DP deficiency is manifested locally at the site of challenge. The absence of lymphocyte accumulation in OVA-challenged DP Ϫ/Ϫ mice is suggestive of a defect in the recruitment of lymphocytes to the site of allergen challenge. Eosinophilic infiltration in allergic asthma is thought to be a consequence of the activation of T H 2 lymphocytes. Consistent with this notion, infiltration of eosinophils did not occur to a significant extent in OVA-challenged DP Ϫ/Ϫ mice. Furthermore, the in vivo administration of PGD 2 into the airway of dogs induced marked eosinophilic infiltration (20) . Transgenic expression of PGD synthetase in the lung also increased both the concentrations of IL-4 and IL-5 and the extent of eosinophilic infiltration in BAL fluid in a mouse OVA-induced asthma model (21) . These various observations suggest that PGD 2 produced in response to allergic challenge acts at DP in the lung to recruit lymphocytes to the site of challenge. Indeed, we observed the marked expression of the DP receptor in bronchiolar and alveolar epithelial cells in the asthmatic airway. The airway epithelium is proposed as a source of proinflammatory cytokines and chemokines in asthma (3), raising the possibility that PGD 2 acting at DP in the epithelium may stimulate the production and release of these mediators.
Is PGD 2 the sole, obligatory mediator of asthma? Although individuals with asthma usually exhibit high concentrations of IgE in serum, the IgE concentration is often not correlated with the incidence of asthma attacks. This dissociation has led to the suggestion that the IgEand mast cell-mediated pathway is important in triggering asthma, but plays a limited role in the chronic phase of an established asthmatic state. The mast cell-derived PGD 2 therefore appears to play an important role that is restricted to the initiation process, and other redundant pathways that evoke asthmatic responses exist. Consistently, we have found that excessive challenge with OVA overcomes the effect of DP deficiency (22) . It is also possible that PGD 2 produced by cells other than mast cells during asthmatic attacks contributes to trigger and/or enhance allergic responses. It was reported that PGD 2 is produced also by macrophages and dendritic cells (23) .
In summary, we have shown that PGD 2 functions as a mediator of allergic asthma. In addition to being produced in the lung, PGD 2 is produced in various other tissues in response to allergic stimuli (24) , suggesting that it may also play an important role in other allergic disorders, such as allergic rhinitis and atopic dermatitis. The DP receptor may thus represent a new therapeutic target for the treatment of such allergic reactions (25). 129/Sv genomic DNA library (Stratagene) with the corresponding cDNA as a probe. The targeting vector was constructed by inserting the neomycin resistance gene (pMC1-neo, Stratagene) into a unique Nhe I site of the first coding exon; this insertion disrupts the DP gene in the sequence encoding the third transmembrane domain of the protein. The herpes simplex virus thymidine kinase gene was inserted upstream. The targeting vector was linearized and introduced into E14-1 embryonic stem cells from 129/Ola mice by electroporation. Clones resistant to both G418 and gancyclovir were isolated and screened for homologous recombination by PCR amplification. Recombination was then confirmed by Southern blot hybridization. Two lines of embryonic stem cells were injected into C57BL/6 blastocysts to generate chimeric male offspring, which were then mated with C57BL/6 females. Pups with an agouti coat were genotyped by Southern blot analysis for determination of germ line transmission. Polyadenylated RNA was prepared from various organs, which were rapidly removed and homogenized in 10 volumes of Trizol (Gibco-BRL) with a Polytron homogenizer. RT-PCR analysis was performed with 10 g of polyadenylated RNA with the forward primer, 5Ј-TCGGTCT T T TATGTGCTCG-TG-3Ј, corresponding to amino acids 57 to 63 in the first coding exon, and the reverse primer, 5Ј-TC-CACGT TACT T TGCTGGGAA-3Ј, corresponding to amino acids 346 to 353 in the second coding exon. Northern blot analysis was performed on 10 g of The human mitochondrial (mt) genome is small (16.5 kb) and encodes 13 respiratory chain subunits, 22 transfer RNAs (tRNAs), and two ribosomal RNAs (rRNAs). Mitochondrial DNA is present at extremely high levels (10 3 to 10 4 copies per cell), and the vast majority of these copies are identical (homoplasmic) at birth (1). Expression of the entire complement of mt genes is required to maintain proper function of the organelle, suggesting that even slight alterations in DNA sequences could have profound effects (2) . It is generally accepted that mtDNA mutations are generated during oxidative phosphorylation through pathways involving reactive oxygen species (ROS). These mutations may accumulate in part because mitochondria lack protective histones and the highly efficient DNA repair mechanisms that are seen in the nucleus (3). Recently, several mtDNA mutations were found specifically in human colorectal cancer (4). To determine whether mt mutations could be identified in other cancer types, we studied primary bladder (n ϭ 14), head and neck (n ϭ 13), and lung (n ϭ 14) tumors (5) . Eighty percent of the mt genome of all the primary tumor samples was polymerase chain reaction (PCR) amplified (6) and sequenced manually (Fig. 1) . Tumor mtDNA was compared with mtDNA from paired blood samples in all cases and mtDNA from corresponding normal tissue when available (7) . Of the 292 sequence variants detected, 196 were previously recorded polymorphisms (2, 8) , whereas 57 were previously unknown polymorphisms (Web table 1) (9). The remaining 39 variants were acquired (somatic) mutations identified in 64% (9 of 14) of the bladder cancer patients, 46% (6 of 13) of the head and neck cancer patients, and 43% (6 of 14) of the lung cancer patients ( Table 1) . Most of these mutations were T-to-C and Gto-A base transitions, indicating possible exposure to ROS-derived mutagens (10) . Similar to the previous observation by Polyak et al. (4) , the majority of the somatic mutations identified here were also homoplasmic in nature. In addition, several of the bladder and head and neck cancers studied here (Table 1 ) had multiple mutations, implying possible accumulation of mtDNA damage.
In the bladder tumors, mutation hot spots were primarily in the NADH (reduced form of nicotinamide adenine dinucleotide) dehydrogenase subunit 4 (ND4) gene (35%) and in the displacement-loop (D-loop) region (30%). The D-loop region is a critical site for both replication and expression of the mt genome because it contains the leading-strand origin of replication and the major promoters for transcription (11) . Many (73%) of the mutations identified within protein-coding regions were silent, except for a (Val 3 Ala) substitution in the NADH dehydrogenase subunit 3 (ND3) and a seven-amino acid deletion in cytochrome b (Cyt b). The D-loop region was also commonly mutated in the head and neck cancer patients (67%). Two of the head and neck tumors (22%) contained mutations in the ND4 gene at nucleotide pairs (nps) 10,822 and 11,150, resulting in amino acid substitutions of Thr 3 Met and Ala 3 Thr, respectively. A similar tendency was observed in the lung cancer patients, demonstrating a high concentration of mutations in the D-loop region (70%).
We hypothesized that the homoplasmic nature of these mutations would make them readily detectable in paired bodily fluids. To test this, we extracted and directly amplified mtDNA from urine samples from patients diagnosed with bladder cancer. All three corresponding urine samples available in this study contained the mutant mtDNA derived from tumor tissues. For example, the mtDNA from a urine sample from bladder cancer patient 799 showed the same nucleotide transition (G 3 A) as seen in the tumor (Fig. 2A) . In all cases, the urine sample contained a relatively pure population of tumor-derived mtDNA, comparable to that of the microdissected tumor sample. Consistent with this observation, saliva samples obtained from head and neck cancer patients contained no detectable wild-type signals (Fig. 2, B and  C) . By sequence analysis alone, we were able to detect mtDNA mutations in 67% (6 of 9) of saliva samples from head and neck cancer patients. In lung cancer cases, we were initially unable to identify mutant bands from paired bronchoalveolar lavage (BAL) fluids because of the substantial dilution of neoplastic cells in BAL fluid (12) (Fig. 2D) . Thus, we applied a more sensitive oligonucleotide-mismatch ligation assay to detect mutated mtDNA. As shown in Fig. 3 , both lung cancer mutations (arrows) were confirmed in tumor mtDNA with more dilute signals in the corresponding BAL samples and no signal in the corresponding normal *To whom correspondence should be addressed. Email: dsidrans@jhmi.edu tissues. Again, we detected the majority of mtDNA mutations (8 of 10) in BAL fluids, with the exception of two cases where the ligation assays were not feasible because of the sequence compositions (16, 183 and 302 nps) adjacent to the mutations.
To quantitate this neoplastic DNA enrichment, we compared the abundance of mt gene mutations with that of nuclear-encoded p53 mutations in bodily fluids using a quantitative plaque assay. Nuclear and mt fragments that contained a mutated sequence were PCR amplified and cloned for plaque hybridization (13) . Two BAL samples from lung cancer patients were chosen for analysis because they had mutations in both the mt and nuclear genomes. For p53 mutations, the percentages of neoplastic cells among normal cells for patients 1113 and 1140 were 0.1 and 3.0, respectively. Remarkably, the abundance of the corresponding mutated mtDNA (MT) was 22 and 52% when compared with the wild-type mt sequence (Fig.  4) . This enrichment of mtDNA is presumably due to the homoplasmic nature of these mutations and the high copy number of mt genomes in cancer cells. Enrichment was further suggested by our observations with paraffin samples of head and neck cancer, where we were able to PCR amplify 2-to 3-kb fragments of mtDNA, but not nuclear p53 gene fragments of over 300 base pairs.
A role for mitochondria in tumorigenesis was hypothesized when tumor cells were found to have an impaired respiratory system and high glycolytic activity (14, 15) . Recent findings elucidating the role of mitochondria in apoptosis (16) and the high incidence of mtDNA mutations in colon cancer (4) further support this hypothesis. Although additional investigation is needed to define the functional importance of mt mutations, our data establish that these mutations are frequent and present at high levels in all of the tumor types examined.
The homoplasmic nature of the mutated mitochondria remains puzzling. It is estimated that each cell contains several hundred to thousands of mitochondria and that each mitochondrion contains 1 to 10 genomes (17) . Conceivably, certain mutated mtDNAs may gain a substantial replicative advantage. For example, mutations in the D-loop regulatory region might alter the rate of DNA replication by modifying the binding affinity of important trans-acting factors. Mitochondria that undergo the most rapid replication are likely to acquire more DNA damage, leading to an accumulation of mutational events. Although the mechanism may vary for other mutations (such as silent mutations in the ND4 gene), the accumulation of a particular mtDNA mutation may become more apparent during neoplastic transformation. Even subtle mtDNA mutations may also gain substantial replicative advantage, perhaps through interactions with important nuclear factors. Homoplasmic transformation of mtDNA was observed in small populations of cells in other nonneoplastic but diseased tissues (18), sometimes associated with aging (19). We hypothesize that, in contrast to classic clonal expansion, the process may occur as "pseudoclonal" selection where stochastic segregation of mitochondria (17 ) together with neoplastic clonal expansion driven by nuclear mutations leads to a homogeneous population of a previously "altered" mitochondrion (Web figure 1) (9) .
The large number of mt polymorphisms identified here and elsewhere (2) likely reflects the high mutation rate of mtDNA, which is thought to be caused mainly by high levels of ROS (20) . In agreement with this, our data imply that constitutive hypervariable areas such as the D-loop region represent somatic mutational hot spots. As further mutations are tabulated in primary tumors, DNA-chip technology can be harnessed to develop high-throughput analyses with sufficient sensitivity to detect these mutations in most bodily fluids (21, 22) . Because of its high copy number, mtDNA may provide a distinct advantage over other nuclear genome-based methods for cancer detection. Table 1 . Summary of mtDNA mutations in primary tumors. Only the D-loop region was analyzed for lung cancer patients 1113, 1140, and 1174. N, sequence obtained from a normal sample; T, mutated sequence in tumor; aa, amino acid; del, deletion; ins, insertion. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; F, Phe; H, His; L, Leu; M, Met; T, Thr; and V, Val.
